AYTU BIOPHARMA, INC Contractual Obligation, to be Paid, Year One
AYTU BIOPHARMA, INC (AYTU) had Contractual Obligation, to be Paid, Year One of $10.13 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligationDueInNextTwelveMonths · last filed 2021-11-15
- 2021-09-30: Contractual Obligation, to be Paid, Year One $10.13M.
- 2021-06-30: Contractual Obligation, to be Paid, Year One $12.30M.
- 2021-03-31: Contractual Obligation, to be Paid, Year One $1.97M.
- 2020-12-31: Contractual Obligation, to be Paid, Year One $5.18M.
| Period end | Contractual Obligation, to be Paid, Year One |
|---|---|
| 2021-09-30 | $10.13M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $12.30M 10-K · filed 2021-09-28 |
| 2021-03-31 | $1.97M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $5.18M 10-Q · filed 2021-02-11 |
| 2020-09-30 | $6.64M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $7.18M 10-K · filed 2020-10-06 |
| 2020-03-31 | $3.27M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $2.40M 10-Q · filed 2020-02-14 |
| 2019-09-30 | $423.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $679.00K 10-K · filed 2019-09-26 |
| 2019-03-31 | $504.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $691.00K 10-Q · filed 2019-05-14 |
| 2018-09-30 | $904.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.06M 10-K · filed 2018-09-06 |
| 2018-03-31 | $386.00K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $570.00K 10-Q · filed 2018-02-08 |
| 2017-09-30 | $755.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $914.00K 10-K · filed 2017-08-31 |
| 2017-03-31 | $513.00K 10-Q · filed 2017-05-11 |
| 2016-12-31 | $4.75M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $10.37M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $9.90M 10-K · filed 2016-09-01 |
| 2016-03-31 | $2.10M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $2.28M 10-Q · filed 2016-02-11 |
| 2015-09-30 | $691.00K 10-Q · filed 2015-11-06 |
| 2014-06-30 | $1.43M 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |